Development and evaluation of the Basic Outcome Measure Protocol for Aphasia (BOMPA)

Abstract

Purpose

The Basic Outcome Measure Protocol for Aphasia (BOMPA) is a practical tool that allows for a quick self-report on quality of life from the perspective of the person with aphasia, as well as a clinical evaluation of aphasia severity and the ability to participate in conversation. The primary aim of this paper is to describe development of BOMPA and report on results of an inter-rater reliability study involving speech-language pathology raters.

Method

The inter-rater reliability study utilised a fully crossed design and included independent ratings of 12 videos by 20 speech-language pathologists.

Result

Results indicate moderate to strong inter-rater reliability among participant speech-language pathology raters (0.65–0.96), as well as when comparing these participant ratings with an expert rater’s gold standard (0.59–0.86).

Conclusion

BOMPA may be a useful outcome measurement tool for time-pressed clinicians in clinical settings.

Keywords:

• aphasia
• evaluation
• conversation
• participation
• severity
• quality of life

Acknowledgements

The authors wish to thank Melodie Chan for her support in the preparation of the manuscript and with the development of BOMPA. The authors also thank Aphasia Institute staff and clients; Eavan Sinden, and Catherine Low for their contributions to BOMPA development; and the SLPs who participated in the inter-rater reliability study.

Declaration of interest

The authors have no financial or non-financial conflicts associated with publication. The BOMPA product may be sold by the Aphasia Institute in the future. The Aphasia Institute is a registered charity and any profits from selling the BOMPA product will go towards sustaining the mission and vision of the agency. There will be no personal gain to any of the authors of the paper through the sale of the BOMPA product.

Supplementary material

Supplemental data for this article can be accessed at http://dx.doi.org/10.1080/17549507.2020.1784278.

Additional information

Funding

This work was supported in part by a grant from Speech-Language & Audiology Canada (SAC) Clinical Research Grants and BMS Group funding.